DarioHealth Corp. Relocates Principal Executive Offices
Ticker: DRIO · Form: 8-K · Filed: Apr 19, 2024 · CIK: 1533998
| Field | Detail |
|---|---|
| Company | Dariohealth CORP. (DRIO) |
| Form Type | 8-K |
| Filed Date | Apr 19, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-address, administrative
TL;DR
DarioHealth moved its main office to NYC, effective April 16th.
AI Summary
DarioHealth Corp. filed an 8-K on April 19, 2024, reporting a change in its principal executive offices to 322 W 57th St, #33B, New York, NY 10019, effective April 16, 2024. The company also confirmed its fiscal year end remains December 31st. This filing does not involve any financial transactions or material business changes.
Why It Matters
A change in principal executive offices can indicate operational shifts or a move to a more strategic location for the company.
Risk Assessment
Risk Level: low — This filing is administrative and reports a change of address, not a material financial event.
Key Players & Entities
- DarioHealth Corp. (company) — Registrant
- 322 W 57th St, #33B, New York, NY 10019 (location) — New Principal Executive Offices
- April 16, 2024 (date) — Effective date of office change
- April 19, 2024 (date) — Filing date of the 8-K
- LabStyle Innovations Corp. (company) — Former Company Name
FAQ
What is the new address for DarioHealth Corp.'s principal executive offices?
The new address is 322 W 57th St, #33B, New York, NY 10019.
When was the change in principal executive offices effective?
The change was effective as of April 16, 2024.
What is the filing date of this Form 8-K?
The Form 8-K was filed on April 19, 2024.
What is DarioHealth Corp.'s fiscal year end?
DarioHealth Corp.'s fiscal year end is December 31st.
Was DarioHealth Corp. previously known by another name?
Yes, the company was formerly known as LabStyle Innovations Corp.
Filing Stats: 466 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-04-19 16:11:30
Key Financial Figures
- $0.0001 — registered Common Stock, par value $0.0001 per share DRIO The Nasdaq Capital M
Filing Documents
- tm2412279d1_8k.htm (8-K) — 26KB
- tm2412279d1_ex3-1.htm (EX-3.1) — 89KB
- tm2412279d1_ex3-2.htm (EX-3.2) — 89KB
- 0001104659-24-049443.txt ( ) — 424KB
- drio-20240416.xsd (EX-101.SCH) — 3KB
- drio-20240416_lab.xml (EX-101.LAB) — 33KB
- drio-20240416_pre.xml (EX-101.PRE) — 22KB
- tm2412279d1_8k_htm.xml (XML) — 4KB
03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On April 16, 2024, DarioHealth Corp. (the "Company") adopted Amended and Restated Bylaws ("Bylaws") with the approval of the Company's Board of Directors. The Bylaws were revised to reduce the quorum requirement at any meeting of the Company's stockholders to thirty-three and one-third percent (33 1/3%) of the stock issued and outstanding and entitled to vote at such meeting.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits 3.1 Amended and Restated Bylaws as amended on April 16, 2024. 3.2 Amended and Restated Bylaws as amended on April 16, 2024 (marked). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: April 19, 2024 DARIOHEALTH CORP. By: /s/ Zvi Ben David Name: Zvi Ben David Title: Chief Financial Officer, Treasurer and Secretary